AZ COVID-19 Vaccine Scores 79% In Pivotal US Trial – Any Hope For A Fresh Start?

Brain Clot Safety Issue Addressed

 
• By Andrew McConaghie

The US FDA will now have the full efficacy data that it wanted from AstraZeneca, but the company still has to deal with concerns over safety and global supply issues.  

AZ COVID Vaccine
The AZ vaccine has shown its most impressive safety and efficacy via real world data in the UK, but the US regulator will focus on the new Phase III results.

More from Clinical Trials

More from R&D